Metastasis to hypopharynx from epidermotropic metastatic malignant melanoma
Drug Discov Ther. 2024 Apr 17. doi: 10.5582/ddt.2024.01017. Online ahead of print.ABSTRACTPrevious reports proposed the concept and criteria of epidermotropic metastatic malignant melanoma (EMMM): (a) dermal involvement equal to or broader than the epidermal involvement, (b) atypical melanocytes within the dermis, (c) thinning of the epidermis, (d) widening of the papillary dermis with an epithelial collarette, and (e) vascular invasion of atypical melanocytes. However, it remains unclear whether EMMM also involves the mucosal epithelium. In this case, the patient was diagnosed with EMMM based on the histopathological find...
Source: Drug Discoveries and Therapeutics - April 17, 2024 Category: Drugs & Pharmacology Authors: Satoru Mizuhashi Azusa Miyashita Haruka Kuriyama Toshihiro Kimura Hisashi Kanemaru Satoru Miyamaru Sho Saeki Satoshi Fukushima Source Type: research
Tuberculosis in pregnancy and assisted reproductive technology
Drug Discov Ther. 2024 Apr 17. doi: 10.5582/ddt.2024.01007. Online ahead of print.ABSTRACTTuberculosis is a chronic infectious disease caused by mycobacterium tuberculosis infection. In the world, tuberculosis is an important factor affecting women's reproductive health, which can cause reproductive tract anatomy abnormalities, embryo implantation obstacles, ovarian reserve and ovulation dysfunction, leading to female infertility. This group of women usually need to seek assisted reproductive technology to conceive. Latent tuberculosis infection during pregnancy has no clinical manifestation, but may develop into active tu...
Source: Drug Discoveries and Therapeutics - April 17, 2024 Category: Drugs & Pharmacology Authors: Wenli Cao Xiayan Fu Haiyang Li Jialu Bei Lisha Li Ling Wang Source Type: research
Bu-Shen-Ning-Xin decoction inhibits macrophage activation to ameliorate premature ovarian insufficiency-related osteoimmune disorder via FSH/FSHR pathway
In conclusion, BSNXD regulated POI-related osteoimmune disorder by suppressing the FSH/FSHR pathway to reduce macrophage activation and further inhibiting osteoclastogenesis.PMID:38631868 | DOI:10.5582/ddt.2024.01006 (Source: Drug Discoveries and Therapeutics)
Source: Drug Discoveries and Therapeutics - April 17, 2024 Category: Drugs & Pharmacology Authors: Hongmei Sun Qing Qi Xinyao Pan Jing Zhou Jing Wang Lisha Li Dajing Li Ling Wang Source Type: research
The prospects of automation in drug discovery research using silkworms
Drug Discov Ther. 2024 Apr 4. doi: 10.5582/ddt.2024.01013. Online ahead of print.ABSTRACTWe have established several models of infectious diseases in silkworms to explore disease-causing mechanisms and identify new antimicrobial substances. These models involve injecting laboratory-cultured pathogens into silkworms and monitoring their survival over a period of days. The use of silkworms is advantageous because they are cost-effective and raise fewer ethical concerns than mammalian subjects, allowing for larger experimental group sizes. To capitalize on these benefits, there is a growing importance in mechanizing and autom...
Source: Drug Discoveries and Therapeutics - April 3, 2024 Category: Drugs & Pharmacology Authors: Atsushi Miyashita Masanobu Miyauchi Fumiaki Tabuchi Source Type: research
Rapamycin vs TORin-1 or Gleevec vs Nilotinib: Simple chemical evolution that converts PAK1-blockers to TOR-blockers or vice versa?
Drug Discov Ther. 2024 Apr 4. doi: 10.5582/ddt.2023.01097. Online ahead of print.ABSTRACTBoth PAK1 (RAC/CDC42-activating kinase 1) and TOR (Target of Rapamycin) are among the major oncogenic/ageing kinases. However, they play the opposite role in our immune system, namely immune system is suppressed by PAK1, while it requires TOR. Thus, PAK1-blockers, would be more effective for therapy of cancers, than TOR-blockers. Since 2015 when we discovered genetically that PDGF-induced melanogenesis depends on "PAK1", we are able to screening a series of PAK1-blockers as melanogenesis-inhibitors which could eventually promote longev...
Source: Drug Discoveries and Therapeutics - April 3, 2024 Category: Drugs & Pharmacology Authors: Hiroshi Maruta Hong He Source Type: research
The prospects of automation in drug discovery research using silkworms
Drug Discov Ther. 2024 Apr 4. doi: 10.5582/ddt.2024.01013. Online ahead of print.ABSTRACTWe have established several models of infectious diseases in silkworms to explore disease-causing mechanisms and identify new antimicrobial substances. These models involve injecting laboratory-cultured pathogens into silkworms and monitoring their survival over a period of days. The use of silkworms is advantageous because they are cost-effective and raise fewer ethical concerns than mammalian subjects, allowing for larger experimental group sizes. To capitalize on these benefits, there is a growing importance in mechanizing and autom...
Source: Drug Discoveries and Therapeutics - April 3, 2024 Category: Drugs & Pharmacology Authors: Atsushi Miyashita Masanobu Miyauchi Fumiaki Tabuchi Source Type: research
Rapamycin vs TORin-1 or Gleevec vs Nilotinib: Simple chemical evolution that converts PAK1-blockers to TOR-blockers or vice versa?
Drug Discov Ther. 2024 Apr 4. doi: 10.5582/ddt.2023.01097. Online ahead of print.ABSTRACTBoth PAK1 (RAC/CDC42-activating kinase 1) and TOR (Target of Rapamycin) are among the major oncogenic/ageing kinases. However, they play the opposite role in our immune system, namely immune system is suppressed by PAK1, while it requires TOR. Thus, PAK1-blockers, would be more effective for therapy of cancers, than TOR-blockers. Since 2015 when we discovered genetically that PDGF-induced melanogenesis depends on "PAK1", we are able to screening a series of PAK1-blockers as melanogenesis-inhibitors which could eventually promote longev...
Source: Drug Discoveries and Therapeutics - April 3, 2024 Category: Drugs & Pharmacology Authors: Hiroshi Maruta Hong He Source Type: research
The prospects of automation in drug discovery research using silkworms
Drug Discov Ther. 2024 Apr 4. doi: 10.5582/ddt.2024.01013. Online ahead of print.ABSTRACTWe have established several models of infectious diseases in silkworms to explore disease-causing mechanisms and identify new antimicrobial substances. These models involve injecting laboratory-cultured pathogens into silkworms and monitoring their survival over a period of days. The use of silkworms is advantageous because they are cost-effective and raise fewer ethical concerns than mammalian subjects, allowing for larger experimental group sizes. To capitalize on these benefits, there is a growing importance in mechanizing and autom...
Source: Drug Discoveries and Therapeutics - April 3, 2024 Category: Drugs & Pharmacology Authors: Atsushi Miyashita Masanobu Miyauchi Fumiaki Tabuchi Source Type: research
Rapamycin vs TORin-1 or Gleevec vs Nilotinib: Simple chemical evolution that converts PAK1-blockers to TOR-blockers or vice versa?
Drug Discov Ther. 2024 Apr 4. doi: 10.5582/ddt.2023.01097. Online ahead of print.ABSTRACTBoth PAK1 (RAC/CDC42-activating kinase 1) and TOR (Target of Rapamycin) are among the major oncogenic/ageing kinases. However, they play the opposite role in our immune system, namely immune system is suppressed by PAK1, while it requires TOR. Thus, PAK1-blockers, would be more effective for therapy of cancers, than TOR-blockers. Since 2015 when we discovered genetically that PDGF-induced melanogenesis depends on "PAK1", we are able to screening a series of PAK1-blockers as melanogenesis-inhibitors which could eventually promote longev...
Source: Drug Discoveries and Therapeutics - April 3, 2024 Category: Drugs & Pharmacology Authors: Hiroshi Maruta Hong He Source Type: research
The prospects of automation in drug discovery research using silkworms
Drug Discov Ther. 2024 Apr 4. doi: 10.5582/ddt.2024.01013. Online ahead of print.ABSTRACTWe have established several models of infectious diseases in silkworms to explore disease-causing mechanisms and identify new antimicrobial substances. These models involve injecting laboratory-cultured pathogens into silkworms and monitoring their survival over a period of days. The use of silkworms is advantageous because they are cost-effective and raise fewer ethical concerns than mammalian subjects, allowing for larger experimental group sizes. To capitalize on these benefits, there is a growing importance in mechanizing and autom...
Source: Drug Discoveries and Therapeutics - April 3, 2024 Category: Drugs & Pharmacology Authors: Atsushi Miyashita Masanobu Miyauchi Fumiaki Tabuchi Source Type: research
Rapamycin vs TORin-1 or Gleevec vs Nilotinib: Simple chemical evolution that converts PAK1-blockers to TOR-blockers or vice versa?
Drug Discov Ther. 2024 Apr 4. doi: 10.5582/ddt.2023.01097. Online ahead of print.ABSTRACTBoth PAK1 (RAC/CDC42-activating kinase 1) and TOR (Target of Rapamycin) are among the major oncogenic/ageing kinases. However, they play the opposite role in our immune system, namely immune system is suppressed by PAK1, while it requires TOR. Thus, PAK1-blockers, would be more effective for therapy of cancers, than TOR-blockers. Since 2015 when we discovered genetically that PDGF-induced melanogenesis depends on "PAK1", we are able to screening a series of PAK1-blockers as melanogenesis-inhibitors which could eventually promote longev...
Source: Drug Discoveries and Therapeutics - April 3, 2024 Category: Drugs & Pharmacology Authors: Hiroshi Maruta Hong He Source Type: research
The prospects of automation in drug discovery research using silkworms
Drug Discov Ther. 2024 Apr 4. doi: 10.5582/ddt.2024.01013. Online ahead of print.ABSTRACTWe have established several models of infectious diseases in silkworms to explore disease-causing mechanisms and identify new antimicrobial substances. These models involve injecting laboratory-cultured pathogens into silkworms and monitoring their survival over a period of days. The use of silkworms is advantageous because they are cost-effective and raise fewer ethical concerns than mammalian subjects, allowing for larger experimental group sizes. To capitalize on these benefits, there is a growing importance in mechanizing and autom...
Source: Drug Discoveries and Therapeutics - April 3, 2024 Category: Drugs & Pharmacology Authors: Atsushi Miyashita Masanobu Miyauchi Fumiaki Tabuchi Source Type: research
Rapamycin vs TORin-1 or Gleevec vs Nilotinib: Simple chemical evolution that converts PAK1-blockers to TOR-blockers or vice versa?
Drug Discov Ther. 2024 Apr 4. doi: 10.5582/ddt.2023.01097. Online ahead of print.ABSTRACTBoth PAK1 (RAC/CDC42-activating kinase 1) and TOR (Target of Rapamycin) are among the major oncogenic/ageing kinases. However, they play the opposite role in our immune system, namely immune system is suppressed by PAK1, while it requires TOR. Thus, PAK1-blockers, would be more effective for therapy of cancers, than TOR-blockers. Since 2015 when we discovered genetically that PDGF-induced melanogenesis depends on "PAK1", we are able to screening a series of PAK1-blockers as melanogenesis-inhibitors which could eventually promote longev...
Source: Drug Discoveries and Therapeutics - April 3, 2024 Category: Drugs & Pharmacology Authors: Hiroshi Maruta Hong He Source Type: research
The prospects of automation in drug discovery research using silkworms
Drug Discov Ther. 2024 Apr 4. doi: 10.5582/ddt.2024.01013. Online ahead of print.ABSTRACTWe have established several models of infectious diseases in silkworms to explore disease-causing mechanisms and identify new antimicrobial substances. These models involve injecting laboratory-cultured pathogens into silkworms and monitoring their survival over a period of days. The use of silkworms is advantageous because they are cost-effective and raise fewer ethical concerns than mammalian subjects, allowing for larger experimental group sizes. To capitalize on these benefits, there is a growing importance in mechanizing and autom...
Source: Drug Discoveries and Therapeutics - April 3, 2024 Category: Drugs & Pharmacology Authors: Atsushi Miyashita Masanobu Miyauchi Fumiaki Tabuchi Source Type: research
Rapamycin vs TORin-1 or Gleevec vs Nilotinib: Simple chemical evolution that converts PAK1-blockers to TOR-blockers or vice versa?
Drug Discov Ther. 2024 Apr 4. doi: 10.5582/ddt.2023.01097. Online ahead of print.ABSTRACTBoth PAK1 (RAC/CDC42-activating kinase 1) and TOR (Target of Rapamycin) are among the major oncogenic/ageing kinases. However, they play the opposite role in our immune system, namely immune system is suppressed by PAK1, while it requires TOR. Thus, PAK1-blockers, would be more effective for therapy of cancers, than TOR-blockers. Since 2015 when we discovered genetically that PDGF-induced melanogenesis depends on "PAK1", we are able to screening a series of PAK1-blockers as melanogenesis-inhibitors which could eventually promote longev...
Source: Drug Discoveries and Therapeutics - April 3, 2024 Category: Drugs & Pharmacology Authors: Hiroshi Maruta Hong He Source Type: research
